<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396747</url>
  </required_header>
  <id_info>
    <org_study_id>CIERA</org_study_id>
    <nct_id>NCT00396747</nct_id>
  </id_info>
  <brief_title>A Comparison of Methotrexate Alone or Combined to Infliximab or to Pulse Methylprednisolone in Early Rheumatoid Arthritis: A Magnetic Resonance Imaging Study</brief_title>
  <official_title>Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the effects of methotrexate (MTX) alone or in
      combination with intravenous (IV) methylprednisolone (MP) or infliximab (IFX) on MRI-detected
      synovitis, bone edema and erosive changes in early rheumatoid arthritis (RA) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of Glucocorticoïds and Infliximab have never been compared in early RA using MRI
      as primary outcome measure. In the current study, we compare the effects of MTX alone or in
      combination with intravenous (IV) methylprednisolone (MP) pulse therapy or IFX on
      MRI-detected synovitis, bone edema and erosive changes in early RA patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI synovitis, bone edema and erosions score</measure>
    <time_frame>baseline, week 18 and 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (DAS Score, ACR response)</measure>
    <time_frame>every 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>every visit</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX + MP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX + IFX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab, methylprednisolone, methotrexate</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate + Methylprednisolone</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate + Infliximab</intervention_name>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients were eligible for this study if they met the American Rheumatism Association
             classification criteria for RA (9), had a disease duration inferior to one year,
             suffered from active disease (defined as the presence of a swollen joint count [SJC] ≥
             6 [by the 66 joints count] and a tender joint count [TJC] ≥ 8 [by the 68 joints
             count]) and had not been treated with MTX before.

          -  Patients were eligible for this study if they met the American Rheumatism Association
             classification criteria for RA (9), had a disease duration inferior to one year,
             suffered from active disease (defined as the presence of a swollen joint count [SJC] ≥
             6 [by the 66 joints count] and a tender joint count [TJC] ≥ 8 [by the 68 joints
             count]) and had not been treated with MTX before.

        Exclusion Criteria:

          -  Exclusion criteria included past/current history of tuberculosis, congestive heart
             disease, past treatment with GC for more than 3 months (and not during the 4 weeks
             before inclusion), previous treatment with more than 2 DMARDs, MTX, IV MP pulse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Durez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Catholique de Louvain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Université catholique de Louvain</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2006</study_first_submitted>
  <study_first_submitted_qc>November 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2006</study_first_posted>
  <last_update_submitted>October 18, 2007</last_update_submitted>
  <last_update_submitted_qc>October 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2007</last_update_posted>
  <keyword>Early rheumatoid arthritis,</keyword>
  <keyword>glucocorticoids,</keyword>
  <keyword>pulse therapy,</keyword>
  <keyword>infliximab,</keyword>
  <keyword>TNF blockade</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Infliximab</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

